Cargando…

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Woo-Baek, Youn, Ho-Joong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939510/
https://www.ncbi.nlm.nih.gov/pubmed/27378126
http://dx.doi.org/10.3904/kjim.2016.017
_version_ 1782442013859250176
author Chung, Woo-Baek
Youn, Ho-Joong
author_facet Chung, Woo-Baek
Youn, Ho-Joong
author_sort Chung, Woo-Baek
collection PubMed
description Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is difficult to recommend guidelines for the prevention or management of anthracycline-induced cardiotoxicity applicable to all cancer types. Therefore, anthracycline-induced cardiotoxicity remains a major limitation in the proper management of cancer patients treated with an anthracycline-combined regimen. Efforts have been extensive to determine the mechanism and treatment of anthracycline-induced cardiotoxicity. Because cardiotoxicity causes irreversible damage to the myocardium, prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops. This article will review the pathophysiological mechanisms of anthracycline-induced cardiotoxicity and strategies for protecting the myocardium from anthracycline.
format Online
Article
Text
id pubmed-4939510
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-49395102016-07-11 Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity Chung, Woo-Baek Youn, Ho-Joong Korean J Intern Med Review Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is difficult to recommend guidelines for the prevention or management of anthracycline-induced cardiotoxicity applicable to all cancer types. Therefore, anthracycline-induced cardiotoxicity remains a major limitation in the proper management of cancer patients treated with an anthracycline-combined regimen. Efforts have been extensive to determine the mechanism and treatment of anthracycline-induced cardiotoxicity. Because cardiotoxicity causes irreversible damage to the myocardium, prevention is a more effective approach than treatment of cardiotoxicity after symptomatic or asymptomatic cardiac dysfunction develops. This article will review the pathophysiological mechanisms of anthracycline-induced cardiotoxicity and strategies for protecting the myocardium from anthracycline. The Korean Association of Internal Medicine 2016-07 2016-07-01 /pmc/articles/PMC4939510/ /pubmed/27378126 http://dx.doi.org/10.3904/kjim.2016.017 Text en Copyright © 2016 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Chung, Woo-Baek
Youn, Ho-Joong
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
title Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
title_full Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
title_fullStr Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
title_full_unstemmed Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
title_short Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
title_sort pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939510/
https://www.ncbi.nlm.nih.gov/pubmed/27378126
http://dx.doi.org/10.3904/kjim.2016.017
work_keys_str_mv AT chungwoobaek pathophysiologyandpreventivestrategiesofanthracyclineinducedcardiotoxicity
AT younhojoong pathophysiologyandpreventivestrategiesofanthracyclineinducedcardiotoxicity